Xenon Pharmaceuticals (XENE) Non Operating Investment Income (2019 - 2022)
Historic Non Operating Investment Income for Xenon Pharmaceuticals (XENE) over the last 4 years, with Q2 2022 value amounting to -$1.3 million.
- Xenon Pharmaceuticals' Non Operating Investment Income fell 747647.06% to -$1.3 million in Q2 2022 from the same period last year, while for Jun 2022 it was -$4.7 million, marking a year-over-year decrease of 108229.43%. This contributed to the annual value of -$719000.0 for FY2021, which is 1807500.0% down from last year.
- Xenon Pharmaceuticals' Non Operating Investment Income amounted to -$1.3 million in Q2 2022, which was down 747647.06% from -$3.4 million recorded in Q1 2022.
- Xenon Pharmaceuticals' 5-year Non Operating Investment Income high stood at -$17000.0 for Q2 2021, and its period low was -$3.4 million during Q1 2022.
- In the last 4 years, Xenon Pharmaceuticals' Non Operating Investment Income had a median value of -$177500.0 in 2020 and averaged -$841833.3.
- In the last 5 years, Xenon Pharmaceuticals' Non Operating Investment Income soared by 7366.55% in 2021 and then tumbled by 747647.06% in 2022.
- Quarter analysis of 4 years shows Xenon Pharmaceuticals' Non Operating Investment Income stood at -$29000.0 in 2019, then plummeted by 868.97% to -$281000.0 in 2020, then surged by 93.95% to -$17000.0 in 2021, then tumbled by 7476.47% to -$1.3 million in 2022.
- Its Non Operating Investment Income was -$1.3 million in Q2 2022, compared to -$3.4 million in Q1 2022 and -$17000.0 in Q2 2021.